Sample size dosage strength pro­por­tion­ality study [Power / Sample Size]

posted by Laura R  – Israel, 2021-02-01 09:19 (76 d 21:39 ago) – Posting: # 22197
Views: 587

Dear Forum,
I was interesting to hear thoughts about the need to power a DP study for a 505b2:
BE between T and R will be demonstrated at one dose level. The PK of the drug is linear over the entire range however because of non-proportionality composition between T strengths we will run also a DP trial (for T only).
Power model at alpha = 0.05 will be used, so the 90% CI of the slope will be compared to the [0.80, 1.25] bounds.

Couldn't find any reference/guidance on the need to base sample size to achieve 80% or 90% power (in our case this will result in a very large study), and from review of precedents this sort of trials are many times non-powered and only descriptive.

Any comment is appreciated.

Best,

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Monday 07:59 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5